U.S. Markets close in 4 hrs 39 mins

Amarin Rises on Priority Review for Vascepa Label Expansion

Zacks Equity Research

Amarin Corporation plc AMRN announced that the FDA has granted priority review to the supplemental new drug application (sNDA) for its sole marketed drug, Vascepa. The sNDA is looking to expand Vascepa’s label as a treatment for reduction of residual cardiovascular risk in patients with persistent elevated triglycerides on statin therapy for LDL-C (bad cholesterol). A decision on approval is expected by Sep 28, 2019.

A potential approval to the label expansion will make Vascepa the first drug for the indication.

Please note that Vascepa is already approved in the United States as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia.

Shares of Amarin rallied 11.6% on May 29 following the news. Amarin’s shares have gained 29.6% so far this year compared with the industry’s increase of 0.9%.


The sNDA includes data from the late-stage cardiovascular outcomes study – REDUCE-IT. In March, Amarin presented updated data from the study, which showed that the drug led to a significant reduction in cardiovascular risk in patients with LDL-C controlled by statin therapy. The relative risk of major adverse CV events (“MACE”) was reduced by 30% upon treatment with Vascepa compared to placebo.

Vascepa also led to a 26% reduction in key secondary composite endpoint of cardiovascular death, heart attacks and stroke. The study also achieved the additional secondary endpoints including reductions in cardiovascular death (20%), fatal or nonfatal heart attacks (31%), fatal or nonfatal stroke (28%), urgent or emergent coronary revascularization (35%) and hospitalization for unstable angina (32%).

Upon potential approval, the drug will face competition from Sanofi SNY and Amgen’s AMGN PCSK9 inhibitors, Praluent and Repatha, respectively.

Amarin Corporation PLC Price


Amarin Corporation PLC Price

Amarin Corporation PLC price | Amarin Corporation PLC Quote

Zacks Rank and Stock to Consider

Amarin is a Zacks Rank #3 (Hold) stock. A better-ranked stock in the biotech sector is Anika Therapeutics Inc. ANIK, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Anika’s earnings estimates have been revised 4.9% upward for 2019 and 9.9% for 2020 over the past 60 days. The stock has gained 13.3% so far this year.

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sanofi (SNY) : Free Stock Analysis Report
Anika Therapeutics Inc. (ANIK) : Free Stock Analysis Report
Amarin Corporation PLC (AMRN) : Free Stock Analysis Report
Amgen Inc. (AMGN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research